Why this Board seat matters
The enterprise develops, produces, processes and markets planting material across crop categories. Its long-term value rests on genetic integrity, research discipline, lawful access to germplasm, reliable trials, grower relationships, seed quality and honest communication of expected performance. A single season can materially influence commercial results, but research, multiplication and stewardship obligations extend across many seasons.
The organisation forms part of a large unlisted corporate house and is strengthening independent governance ahead of a more ambitious phase of research and market expansion. The Board requires a Director who understands that biological variation is real, yet cannot be used to excuse weak experimental design, inadequate isolation, poor inventory control or exaggerated product claims.
The stewardship brief
The Director will protect the scientific and ethical foundations of the seed portfolio while challenging the economics of research, multiplication, launches and inventory. The role spans germplasm rights, breeding data, trial design, production quality, grower contracts, seasonal forecasting, complaint handling, pricing conduct, climate resilience and succession in critical scientific roles.
Eight strategic accountabilities
-
Germplasm rights and genetic identity. Oversee provenance, access permissions, ownership, licensing, benefit obligations, storage, access control and genetic identity. Research urgency cannot justify uncertain rights or poorly governed transfers.
-
Trial integrity and reproducibility. Examine site selection, controls, randomisation, data capture, missing observations, protocol deviations, adverse results and statistical interpretation. Management should report the full evidence base, not only favourable locations or seasons.
-
Variety advancement decisions. Require explicit advancement gates covering agronomic value, stability, disease response, quality, farmer fit, production feasibility, regulatory status and commercial economics. Termination of weak candidates should be recognised as disciplined innovation.
-
Seed production and genetic purity. Govern foundation material, grower selection, isolation, field inspection, harvest segregation, processing, testing, treatment, packaging and lot release. Deviations must remain traceable to affected lots and customers.
-
Farmer and channel conduct. Review performance claims, demonstration practices, pricing, credit, returns, complaint resolution, counterfeit response and the clarity of agronomic requirements. Marketing should distinguish potential from guaranteed field outcome.
-
Seasonal inventory and working capital. Challenge demand forecasts, carry-over germination, treatment life, obsolete varieties, channel stock, returns and provisioning. Production optimism should not defer recognition of unsaleable biological inventory.
-
Climate and portfolio resilience. Test genetic and crop concentration, trial diversity, parent-line vulnerability, production geographies, water dependence and response to shifting pest, disease and weather patterns.
-
Research capital and scientific succession. Allocate investment across near-term products, long-cycle programmes, data capability, protected environments, partnerships and talent. Secure succession for breeders and technical custodians whose knowledge cannot be replaced quickly.
A seasonal Board calendar
The Director will encourage the Board to organise oversight around biological decision points rather than quarterly reporting alone. Pre-season reviews should address portfolio, production plans, parent material, contracts and inventory carry-over. In-season reviews should focus on field quality, isolation, weather, disease and forecast changes. Post-harvest reviews should reconcile expected and actual production, quality release, processing loss, complaints and cash conversion.
Material product launches should include evidence across representative conditions, a clear agronomic positioning, seed-production feasibility, stewardship requirements, channel training, complaint readiness and downside inventory. Research partnerships and licences should state data rights, publication, germplasm custody, improvement ownership, territory and termination arrangements.
Evidence and assurance
The Board should receive genetic-purity exceptions; trial deviations; advancement and termination decisions; seed-production variance; germination and quality trends; lot holds and recalls; complaints by root cause; counterfeit cases; channel inventory; ageing and provisions; research milestones; germplasm access; critical-scientist retention; and seasonal cash requirements.
Assurance should trace selected varieties from germplasm and trials through multiplication, processing, release and complaint. It should also test inventory, grower payments, channel returns, product claims, licence royalties and access to research data. Scientific staff must have a protected route to report data manipulation, premature advancement or stewardship concerns.
Leadership profile
Candidates should have at least 25 years of senior experience across agricultural inputs, plant science, seed, food or life sciences, research governance, production, quality, rural markets, audit, finance or large private-company boards. The Board is open to former CEOs, research heads, crop-business leaders, CFOs, stewardship executives, supply-chain leaders and experienced Independent Directors.
The appointee should be able to respect scientific uncertainty while demanding decision-quality evidence. Experience with long innovation cycles, biological inventory, grower networks, intellectual property, climate adaptation, rural conduct or family-controlled corporate governance will be advantageous.
Statutory readiness and conflicts
The candidate must satisfy the company's enhanced independence standard. Relationships involving promoter-family interests, competitors, research institutions, germplasm owners, growers, distributors, testing laboratories, investors, auditors or government-linked programmes must be declared.
The Board position may not be used to obtain licences, research funding, distribution, production contracts, testing assignments or consulting work. Confidential genetic and research information requires enhanced handling.
Value expected in year one
By the end of the first year, the Board expects clearer germplasm accountability, credible trial challenge, documented advancement gates, better genetic-purity assurance, realistic seasonal inventory and a farmer-complaint loop that changes products and practices. The Director should leave the enterprise more capable of pursuing scientific ambition without compromising rights, evidence or farmer trust.